Protection against diet-induced obesity and obesityrelated insulin resistance in Group 1B PLA 2-deficient mice. Am J Physiol Endocrinol Metab 283: E994-E1001, 2002. First published July 30, 2002 10.1152/ajpendo.00110. 2002-Group 1B phospholipase A 2 (PLA2) is an abundant lipolytic enzyme that is well characterized biochemically and structurally. Because of its high level of expression in the pancreas, it has been presumed that PLA 2 plays a role in the digestion of dietary lipids, but in vivo data have been lacking to support this theory. Our initial study on mice lacking PLA 2 demonstrated no abnormalities in dietary lipid absorption in mice consuming a chow diet. However, the effects of PLA 2 deficiency on animals consuming a high-fat diet have not been studied. To investigate this, PLA 2 ϩ/ϩ and PLA2 Ϫ/Ϫ mice were fed a western diet for 16 wk. The results showed that PLA 2 Ϫ/Ϫ mice were resistant to high-fat diet-induced obesity. This observed weight difference was due to decreased adiposity present in the PLA 2 Ϫ/Ϫ mice. Compared with PLA 2 ϩ/ϩ mice, the PLA2 Ϫ/Ϫ mice had 60% lower plasma insulin and 72% lower plasma leptin levels after high-fat diet feeding. The PLA 2 Ϫ/Ϫ mice also did not exhibit impaired glucose tolerance associated with the development of obesityrelated insulin resistance as observed in the PLA 2 ϩ/ϩ mice. To investigate the mechanism by which PLA 2 Ϫ/Ϫ mice exhibit decreased weight gain while on a high-fat diet, fat absorption studies were performed. The PLA 2 Ϫ/Ϫ mice displayed 50 and 35% decreased plasma [ 3 H]triglyceride concentrations 4 and 6 h, respectively, after feeding on a lipidrich meal containing [ 3 H]triolein. The PLA2 Ϫ/Ϫ mice also displayed increased lipid content in the stool, thus indicating decreased fat absorption in these animals. These results suggest a novel role for PLA 2 in the protection against dietinduced obesity and obesity-related insulin resistance, thereby offering a new target for treatment of obesity and diabetes.
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phospholipase A 2; lipase; pancreatic enzymes; animal models; lipid absorption THE PHOSPHOLIPASE A 2 (PLA 2 ) lipolytic enzyme is an abundant protein secreted by the pancreas in response to food intake. It belongs to the Group 1 class B type of secretory PLA 2 (7) and is capable of hydrolyzing the fatty acyl bond at the sn-2 position of phospholipids to generate free fatty acids and lysophospholipids in the intestinal lumen. In addition to its prominent expression in the pancreas, the Group IB PLA 2 is also expressed in other tissues (14, 30, 31, 33) . Phospholipase A 2 has been one of the most extensively studied enzymes in terms of structure and mechanism of action, due to its abundant availability, stability, and ease of isolation. Despite the wealth of information known about the biochemical and structural characteristics of this enzyme (7, 8) , the exact physiological function of PLA 2 has not been completely delineated.
Phospholipids entering the digestive tract from the diet and bile comprise the second most abundant dietary lipid class found in the intestinal lumen (5) . Therefore, it has been suggested that PLA 2 functions in hydrolyzing these phospholipids to forms that can be absorbed by the enterocytes. Various in vitro and in vivo studies have also implied that PLA 2 hydrolysis of phospholipids in the intestinal lumen is required for the efficient absorption of cholesterol from the diet. Studies in rats and humans have shown that intraduodenal infusion of phosphatidylcholine results in decreased cholesterol absorption compared with subjects infused with lower levels of phosphatidylcholine (2, 17) . Mackay et al. (24) identified PLA 2 as the major protein in pancreatic extract that mediates cholesterol transport in Caco-2 cells. The addition of PLA 2 relieved the phosphatidylcholine inhibition of cholesterol transport from bile salt micelles to Caco-2 cells (18) . In addition, our laboratory (39) has shown that PLA 2 hydrolysis of phospholipids on the surface of lipid emulsions was required before pancreatic lipase digestion of triglycerides in the core of lipid emulsions, therefore suggesting a role for PLA 2 in fat absorption.
To investigate the role of PLA 2 in intestinal lipid digestion and transport, we recently generated mice lacking PLA 2 . Using both lymph fistula and singledose, dual-isotope fecal recovery methods, we demonstrated that mice deficient in PLA 2 had no differences in the absorption of dietary lipids compared with wildtype mice (30) . We concluded that, although phospholipid digestion in the intestinal lumen is a prerequisite for efficient absorption of dietary lipids, additional enzyme(s) in the digestive tract can compensate for the lack of PLA 2 in catalyzing phospholipid digestion and facilitating lipid absorption in the PLA 2 knockout mice (29) . However, these studies were performed under basal chow-fed dietary conditions; therefore, dietary lipid absorption in the PLA 2 knockout mice consuming a high-fat diet is not known.
The goal of the present study was to assess the lack of PLA 2 in mice fed a western-type, high-fat/high-cholesterol diet. We hypothesize that the compensatory mechanisms present to compensate for the absence of PLA 2 under basal chow-fed conditions may be overcome by feeding mice a high-fat diet. We report that PLA 2 -deficient mice are resistant to high-fat diet-induced obesity and that the mechanism for this effect is most likely due to decreased dietary fat absorption.
EXPERIMENTAL PROCEDURES
Generation and maintenance of PLA2-deficient mice. The strategy used to disrupt the PLA2 gene to generate PLA2-deficient mice was described previously (29) . All animals used in these studies were back-crossed seven times into the C57BL/6 background and were genotyped by PCR as previously described (29) . The mouse colony was maintained in a temperature-and humidity-controlled room with a 12:12-h light-dark cycle and fed a rodent chow (LM485; HarlanTeklad, Madison, WI) with free access to water. All animal protocols used in this study were approved by the Institutional Animal Care and Use Committee at the University of Cincinnati.
Diet-induced obesity study. Wild-type (PLA 2 ϩ/ϩ ) and PLA2-deficient (PLA2 Ϫ/Ϫ ) mice were fed a standard mouse chow (LM485) or a western-type, high-fat/high-cholesterol diet containing 21% fat and 0.15% cholesterol by weight (TD88137, Harlan Teklad) for 16 wk. For the insulin tolerance test studies, PLA 2 ϩ/ϩ and PLA2 Ϫ/Ϫ mice were fed a high-fat/high carbohydrate diet (no. F3282; Bioserve Industries, Frenchtown, NJ), which contained 35.5% (wt/wt) fat (primarily lard) and 36.6% carbohydrate (primarily sucrose), for 14 wk. Mice had free access to water during the study period. At the beginning of the diet study, mice were 8-10 wk of age. Body weights were recorded throughout the experimental feeding period.
Food consumption studies. At week 14 of the experimental diet period, individually caged mice were given preweighed food, and the amount of food consumed was determined over a 24-h period for 5 days. The results are expressed as grams of food consumed per day.
Glucose tolerance tests. After an overnight fast, PLA 2 ϩ/ϩ and PLA2 Ϫ/Ϫ male mice consuming either the basal low-fat or the western-type diet for 15 wk were injected intraperitoneally with a bolus load of glucose (2 g/kg body wt). Blood was obtained from the tail vein before and 15, 30, 60, and 120 min after glucose administration. Blood glucose was measured using an automated glucose analyzer (Elite XL; Bayer, Elkhart, IN).
Insulin tolerance tests. After a 4-h fast, PLA 2 ϩ/ϩ and PLA2 Ϫ/Ϫ female mice consuming either the basal low-fat or high-fat/high-carbohydrate diet for 14 wk were injected intraperitoneally with bovine insulin (1 U/kg body wt; Sigma Chemical, St. Louis, MO). Blood was obtained for glucose determination from the tail vein before and 15, 30, and 60 min after insulin administration.
Euthanasia. After the 16-wk experimental feeding period, the mice were fasted for 4 h and then anesthetized by intraperitoneal injection with a solution composed of ketamine (80 mg/kg body wt; Fort Dodge Laboratories, Fort Dodge, IA) and xylazine (16 mg/kg; Butler, Columbus, OH) diluted in 0.9% saline. Body temperature was determined using a rectal thermometer. Blood was removed by cardiac puncture into tubes containing 1 mM EDTA. Adipose (epididymal and uterine fat pads) and brown adipose (intrascapular) tissue, and liver, heart, spleen, lungs, and kidneys were removed, and wet weight was recorded.
Plasma chemistries. Plasma was obtained by low-speed centrifugation of the blood samples. Plasma triglyceride, cholesterol, and free fatty acid concentrations were determined by colorimetric assays from Wako Chemicals (Richmond, VA). Plasma leptin and insulin concentrations were measured using radioimmunoassay kits from Linco Research (St. Charles, MO). Blood glucose was measured as described in Glucose tolerance tests. Results from male and female mice were averaged together because there were no apparent differences based on the sex of the animal. Free fatty acid concentrations in plasma were determined only from the female mice.
Postprandial fat absorption. Mice maintained on the basal low-fat diet or the western diet for 4 wk were fasted overnight. The following morning, the mice were injected with 12.5 mg of Triton WR-1339 to block lipolysis (1). Ten minutes later, the mice received an intragastric load of 1 Ci of [ 3 H]triolein (Amersham Pharmacia Biotech, Piscataway, NJ) in 50 l of olive oil. The mice were allowed access to water but not food during the course of the experiment. Blood samples were taken 1, 2, 4, and 6 h after gavage by tail bleeding. Radioactivity appearing in plasma was determined by liquid scintillation counting.
Fecal lipid analysis. Feces were collected from mice fed the western diet for 4 wk over a 24-h period. Mice in each group were housed four per cage; therefore, results represent data from pooled fecal samples. The stool samples were dried to a constant weight, and the lipids were extracted from 100 mg of dried feces as described (32) and analyzed by thin-layer chromatography as described (3, 23) .
Statistical analysis. All results are presented as means Ϯ SD. Differences between the two genotypes were determined by Student's t-test or the Mann-Whitney rank sum test. Differences in the body weight growth curves, glucose tolerance tests, and insulin tolerance tests were determined by one-way ANOVA followed by the Tukey-Kramer tests. P Ͻ 0.05 was accepted as statistically significant. All statistical analysis was completed using the SigmaStat software from Jandel (San Rafael, CA).
RESULTS
Mice lacking PLA 2 have normal growth, lipid metabolism, and reproductive functions while maintained on a basal low-fat diet (Ref. 29 and unpublished observations). To assess the lack of PLA 2 on mice fed a western-type high-fat/high-cholesterol diet for an extended period of time, wild-type (PLA 2 ϩ/ϩ ) and PLA 2 knockout (PLA 2 Ϫ/Ϫ ) male and female mice were fed either a standard mouse chow or a high-fat/high-cholesterol (21% fat, 0.15% cholesterol) diet for 16 wk. There was no difference in body weight between PLA 2 ϩ/ϩ and PLA 2 Ϫ/Ϫ mice when fed the basal low-fat diet (males: 25.3 Ϯ 3.4 vs. 23.8 Ϯ 4.0 g; females: 23.9 Ϯ 4.0 vs. 21.6 Ϯ 0.60 g, respectively). In contrast, the PLA 2 ϩ/ϩ male and female mice gained significantly more weight than the PLA 2 Ϫ/Ϫ mice upon being fed the western diet (Fig. 1) . This resulted in ϳ57 and 40% more weight gained by the male (Fig. 1A, inset) and female (Fig. 1B , inset) PLA 2 ϩ/ϩ mice compared with the PLA 2 Ϫ/Ϫ mice after feeding on the high-fat diet for 16 wk.
To account for the differences in weight gain between the PLA 2 ϩ/ϩ and PLA 2 Ϫ/Ϫ mice, various tissues were removed and weighed. Under low-fat dietary conditions, there were no differences in epididymal and uterine fat pad, brown fat, and liver weights between male and female PLA 2 ϩ/ϩ and PLA 2 Ϫ/Ϫ mice (Fig. 2, A  and B) . In contrast, the PLA 2 Ϫ/Ϫ mice had ϳ50% lower epididymal and uterine fat pad weight compared with PLA 2 ϩ/ϩ mice (Fig. 2, C and D) . The increased adiposity was specific for white fat, as there was no difference in brown adipose mass between the two genotypes after high-fat dietary treatment (Fig. 2, C and D) . Male PLA 2 Ϫ/Ϫ mice also had ϳ36% lower liver weight compared with the PLA 2 ϩ/ϩ mice (Fig. 2C) . However, this difference in liver weight was not apparent in the female mice (Fig. 2D ). There were also no significant differences in heart, spleen, lung, and kidney weights between the PLA 2 ϩ/ϩ and PLA 2 Ϫ/Ϫ mice fed the western diet (data not shown). These data suggest that the observed weight difference among the mice fed the western diet was due to increased adiposity in the wild-type mice.
In addition to differences in body weight gain and adiposity upon feeding on a high-fat/high-cholesterol diet, the PLA 2 Ϫ/Ϫ mice had decreased fasting plasma leptin and insulin concentrations compared with the PLA 2 ϩ/ϩ mice ( Table 1) . The difference in leptin levels is most likely due to changes in adipose tissue observed between the two groups of mice. In contrast, no signif- and PLA2 Ϫ/Ϫ mice after feeding on a western-type diet for 16 wk. Male (A) and female (B) mice 8-10 wk of age were placed on diet containing 21% fat and 0.15% cholesterol (wt/wt) for 16 wk. Body weight of wild-type (F) and PLA2-null (E) mice was determined every 2 wk. The inset in each panel shows the weight gained from PLA2 ϩ/ϩ (filled bars) and PLA2 Ϫ/Ϫ (hatched bars) mice after 16 wk. Data points represent means Ϯ SD from 4 animals in each group. * Significant difference between the groups, P Ͻ 0.05. icant difference was observed in fasting plasma glucose and free fatty acid concentrations (Table 1 ). However, there was a consistent trend toward decreased (20%) fasting glucose levels in the PLA 2 Ϫ/Ϫ mice. Plasma cholesterol and triglyceride levels were similar between the PLA 2 ϩ/ϩ and PLA 2 Ϫ/Ϫ mice after high-fat dietary treatment (Table 1 ).
It appears that the high-fat-fed PLA 2 ϩ/ϩ mice are more insulin resistant than the high-fat-fed PLA 2 Ϫ/Ϫ mice because the increased fasting plasma insulin concentrations are necessary to maintain normal plasma glucose concentrations. To test glucose metabolism directly in these animals, glucose tolerance tests were performed on PLA 2 ϩ/ϩ and PLA 2 Ϫ/Ϫ mice under basal low-fat dietary conditions when the animals were similar in weight and adiposity and after feeding on a high-fat diet. There was no difference in glucose metabolism between the PLA 2 ϩ/ϩ and PLA 2 Ϫ/Ϫ mice consuming the chow diet (Fig. 3A) . In contrast, after highfat feeding, the PLA 2 Ϫ/Ϫ mice displayed lower blood glucose concentrations 15 and 30 min after intraperitoneal glucose administration compared with those observed in the PLA 2 ϩ/ϩ mice (Fig. 3B ). In addition, insulin levels 30 min after glucose injection were 45% lower (1.15 Ϯ 0.28 vs. 0.63 Ϯ 0.08 ng/ml; P Ͻ 0.05) in the PLA 2 Ϫ/Ϫ mice. These data demonstrate that highfat-fed PLA 2 ϩ/ϩ mice have impaired glucose tolerance due to the development of obesity-related insulin resistance, whereas high-fat-fed PLA 2 Ϫ/Ϫ mice maintained normal glucose tolerance.
To test directly the development of obesity-related insulin resistance in these animals, insulin tolerance tests were performed. Both the PLA 2 ϩ/ϩ and PLA 2 Ϫ/Ϫ mice were fed a low-fat or a high-fat/high-carbohydrate diet for 14 wk. The latter diet has been shown previously to induce obesity and insulin resistance in C57BL/6 mice (36, 37). Interestingly, female PLA 2 Ϫ/Ϫ mice exhibited increased glucose disposal 30 min after insulin injection compared with PLA 2 ϩ/ϩ mice under low-fat feeding conditions (Fig. 4A) . After feeding on the high-fat/high-carbohydrate diet for 14 wk, the PLA 2 Ϫ/Ϫ mice had lower blood glucose levels 15, 30, and 60 min after insulin injection compared with PLA 2 ϩ/ϩ mice (Fig. 4B) . These results confirmed that PLA 2 Ϫ/Ϫ mice were protected against the development of high-fat-induced insulin resistance. The data also suggest that PLA 2 Ϫ/Ϫ mice have improved insulin sensitivity compared with PLA 2 ϩ/ϩ mice, even under lowfat feeding conditions.
To examine potential mechanisms for the resistance to diet-induced obesity in the PLA 2 Ϫ/Ϫ mice, we performed studies to measure food consumption, body temperature, and postprandial fat absorption. There was no difference in the amount of food consumed per day or resting body temperature between the PLA 2 ϩ/ϩ and PLA 2 Ϫ/Ϫ mice (Table 1 ). These data suggest that caloric intake and energy expenditure are not contributing to the resistance to diet-induced obesity in the PLA 2 Ϫ/Ϫ mice. To examine postprandial fat absorption, we injected the mice fed the basal low-fat diet or the high-fat diet for 4 (Fig. 5B ). In addition, there were no significant differences in [ decreased postprandial fat absorption observed in the PLA 2 Ϫ/Ϫ mice was not due to increased intestinal retention of radiolabel, thus suggesting suboptimal lipid digestion and/or uptake in the intestinal lumen of PLA 2 Ϫ/Ϫ mice. The possible difference in fat absorption efficiency between PLA 2 ϩ/ϩ and PLA 2 Ϫ/Ϫ mice was addressed directly by measuring their fecal lipid output after they were fed the western diet for 4 wk. Fecal lipids were extracted and analyzed by TLC analysis. There was increased lipid in the form of triglycerides, fatty acids, and a lipid band migrating with cholesteryl ester in the PLA 2 Ϫ/Ϫ mice compared with that observed in PLA 2 ϩ/ϩ mice (Fig. 6 ). Because the diet contains relatively small amounts of cholesteryl ester, the identity of the fastest migrating band may be retinyl ester, which is known to co-migrate with cholesteryl ester. These data provided additional supporting evidence to document that mice lacking PLA 2 have increased fecal lipid output when maintained on a high-fat diet.
DISCUSSION
Obesity has developed into a significant health problem in westernized societies over the past 20 years due to its association with various chronic diseases such as non-insulin-dependent diabetes (type 2 diabetes), cardiovascular disease, and cancer (10, 19) . The increased prevalence of obesity has been attributed to the increased availability and consumption of fat-rich foods and reduced physical activity (35) . This has led many researchers to develop animal models that will allow for the study of the mechanisms by which diet-induced obesity contributes to various disease states.
The C57BL/6 mouse has been shown previously to be a good model for studying diet-induced obesity and diabetes. It develops obesity, insulin resistance, and hyperlipidemia resembling human type 2 diabetes after feeding on a western-type, high-fat diet (22, (36) (37) (38) . Results obtained from our wild-type mice are consistent with these previous reports. Interestingly, C57BL/6 mice with a PLA 2 -null mutation were resistant to diet-induced obesity. This resulted in these animals being hypoinsulinemic, hypoleptinemic, and more insulin sensitive compared with their obese wildtype counterparts. The phenotype of these PLA 2 Ϫ/Ϫ mice is similar to that observed in mice lacking the acyl-CoA:diacylglycerol transferase (Dgat) gene (34) and to the phenotype of animals lacking the protein tyrosine phosphatase-1B (PTP-1B) gene (9) . In the Dgat Ϫ/Ϫ mice, obesity resistance was attributed to increased energy expenditure and increased activity (34) . Obesity resistance and increased insulin sensitivity in the PTP-1B Ϫ/Ϫ mice was due to alteration in fat metabolism and increased energy expenditure as a conse- quence of alterations in the insulin-signaling pathway in muscle (20) . Because the amount of food eaten and resting body temperature were similar between PLA 2 ϩ/ϩ and PLA 2 Ϫ/Ϫ mice, we conclude that decreased caloric intake and increased energy expenditure are not contributing to the resistance to dietinduced obesity in the PLA 2 Ϫ/Ϫ mice. In contrast, the increased fecal lipid output observed in the PLA 2 Ϫ/Ϫ mice suggests that the most likely mechanism to account for the observed difference in diet-induced obesity is reduced fat absorption in the PLA 2 Ϫ/Ϫ mice after high-fat feeding.
Previous studies from our laboratory (29) have shown that PLA 2 Ϫ/Ϫ mice display normal lipid absorption efficiency when fed a low-fat diet and respond to high-fat feeding with increased plasma cholesterol and triglyceride levels to the same extent as that observed in the PLA 2 ϩ/ϩ mice. These results are consistent with previous observations that additional phospholipase(s) in the intestine can partially compensate for the lack of PLA 2 in the PLA 2 Ϫ/Ϫ mice (29) . The reduced fat absorption efficiency in these animals after chronic feeding on a high-fat diet suggested that these compensatory phospholipases are not sufficient for complete fat digestion under high-fat loading conditions and that PLA 2 is required for optimal lipid digestion and absorption. The mechanism by which PLA 2 inhibits fat absorption upon high-fat feeding is likely related to the requirement for both pancreatic triglyceride lipase and PLA 2 in complete fat digestion before its absorption by intestinal cells (18, 24, 39) . Previous studies have clearly documented that inhibition of fat absorption by pancreatic triglyceride lipase inhibitors is effective in weight reduction in obese patients (25, 28) . The present study reveals that reducing the level and activity of PLA 2 is also effective in reducing fat absorption and weight gain.
An explanation to account for these data is that PLA 2 activity and/or its presence is necessary for the upregulation of fat absorption pathways that are induced by high-fat feeding. One possible mechanism by which this may occur is its putative role in the release of digestive enzymes and/or hormones from the pancreas. It is well established that high-fat feeding results in an increase in pancreatic lipase synthesis and secretion from pancreatic acinar cells (4) . This presumably occurs because more lipase is needed to digest the increased amounts of fat entering the small intestine. PLA 2 may be necessary for the upregulation of lipase from pancreatic acinar cells under high-fat conditions. This may occur either through hydrolysis of membrane phospholipids, thereby modifying the properties of the membranes favoring the secretory process, or, alternatively, PLA 2 -catalyzed hydrolysis of phospholipids may generate lipid-signaling molecules, such as lysophospholipids, that are mediators of the secretory process.
Another possible route by which PLA 2 may influence dietary lipid absorption is through an indirect mechanism mediated by its regulation of secretin release. This gastrointestinal hormone is known to be important in the pancreatic adaptation to dietary fat (4). It has also been shown to stimulate insulin secretion and enhance the insulin response to glucose (13) . Recent studies have identified the Group 1B PLA 2 as the secretin-releasing factor in the intestinal lumen (6, 21) . Because secretin release is stimulated by fat feeding, it is possible that PLA 2 Ϫ/Ϫ mice have a reduced secretin level due to their lack of this secretin-releasing factor. This, in turn, may influence the fat-stimulated release of lipase leading to reduced fat absorption in these animals. Additional studies will need to be conducted to test this hypothesis.
Although the decreased level of fat absorption is the most likely cause of the protection against diet-induced obesity and obesity-related insulin resistance observed in the PLA 2 Ϫ/Ϫ mice, other mechanisms may also contribute to this observed phenotype. The increased glucose disposal in response to insulin challenge observed in the PLA 2 Ϫ/Ϫ mice under low-fat-feeding conditions suggests that PLA 2 gene inactivation may also alter insulin-signaling pathways in a manner similar to that observed in the PTP-1B Ϫ/Ϫ mice (9, 20) . Previous studies have shown that the Group 1B PLA 2 is also expressed in other tissues in addition to its prominent expression in the pancreas (14, 30, 31, 33) . The peripheral PLA 2 interacts with specific receptors and modulates cell functions (15) . Thus it is possible that defects in PLA 2 interaction with PLA 2 receptors, such as those observed in PLA 2 -deficient mice, may influence insulin sensitivity in a favorable manner. In support of this hypothesis is the report that PLA 2 receptor-defective mice are more resistant to endotoxic shock due to the reduced plasma level of tumor necrosis factor-␣ (TNF-␣) (16) . This cytokine confers insulin resistance in cells by regulating glucose transporter synthesis and by interfering with insulin signaling (26) . Accordingly, Group 1B PLA 2 deficiency may lower TNF-␣ production and increase insulin sensitivity in this manner. Also, cell culture data have suggested that PLA 2 participates directly in insulin secretion from pancreatic islets (11, 12, 27) . Challenging the PLA 2 Ϫ/Ϫ mice with a high-carbohydrate diet without fat may help to elucidate a role for PLA 2 in insulin signaling.
In summary, we report that mice lacking Group 1B PLA 2 are resistant to diet-induced obesity. This most likely occurs through suppression of dietary fat absorption under high-fat-feeding conditions. Breeding the PLA 2 -deficient mice to various genetic models of obesity will provide exciting tools to understand the mechanisms of PLA 2 on energy metabolism. Finally, regardless of the precise mechanism by which PLA 2 deficiency results in protection against diet-induced obesity and obesity-related insulin resistance, these results offer a novel therapeutic strategy, i.e., the inhibition of Group 1B PLA 2 activity, for the treatment of obesity and type 2 diabetes.
